Table 1 Selected patient and tumour characteristics.
| Â | Total N= 189 | Group A (CP) N= 96 | Group B (CLD) N= 93 |
|---|---|---|---|
Age (years) | Â | Â | Â |
Median (range) | 63 (37-89) | 63 (37-81) | 62 (38-89) |
Performance status | Â | Â | Â |
0 | 117 (62) | 62 (65) | 55 (59) |
1 | 57 (30) | 27 (28) | 30 (32) |
2 | 1 (1) | 0 (0) | 1 (1) |
Unknown | 14 (7) | 7 (7) | 7 (8) |
Stage at diagnosis | Â | Â | Â |
I | 14 (7) | 9 (9) | 5 (5) |
II | 16 (9) | 9 (9) | 7 (8) |
III | 118 (62) | 56 (58) | 62 (67) |
IV | 28 (15) | 15 (16) | 13 (14) |
Unknown | 13 (7) | 7 (7) | 6 (7) |
Histologic grade | Â | Â | Â |
I | 13 (7) | 8 (8) | 5 (5) |
II | 57 (30) | 27 (28) | 30 (32) |
III | 92 (49) | 48 (50) | 44 (47) |
IV | 3 (2) | 1 (1) | 2 (2) |
Unknown | 24 (13) | 12 (13) | 12 (13) |
Histologic type | Â | Â | Â |
Serous | 143 (76) | 71 (74) | 72 (77) |
Mucinous | 3 (2) | 0 (0) | 3 (3) |
Endometroid | 13 (7) | 6 (6) | 7 (8) |
Clear cell | 6 (3) | 3 (3) | 3 (3) |
Other | 14 (7) | 9 (9) | 5 (5) |
Unknown | 10 (5) | 7 (7) | 3 (3) |
Prior therapy | Â | Â | Â |
Surgery | 161 (85) | 85 (89) | 76 (82) |
Taxane containing therapy | 170 (90) | 84 (88) | 86 (93) |
Number of prior chemotherapy lines | Â | Â | Â |
1 | 181 (96) | 92 (96) | 89 (96) |
> = 2 | 8 (4) | 4 (4) | 4 (4) |
Sites of disease | Â | Â | Â |
Abdominal | 95 (50) | 49 (51) | 46 (50) |
Abdominal and pleural effusion or ascites | 43 (23) | 18 (19) | 25 (27) |
Extra-abdominal | 1 (1) | 1 (1) | 0 (0) |
Both | 9 (5) | 5 (5) | 4 (4) |
Ascites or pleural effusion and elevated CA125 | 14 (7) | 10 (10) | 4 (4) |
Elevated CA 125 as the only evidence of disease | 16 (8) | 7 (7) | 9 (10) |
Unknown | 11 (6) | 6 (6) | 5 (5) |
Platinum free interval | Â | Â | Â |
6-12 months | 54 (29) | 32 (33) | 22 (23) |
12.1-24 months | 70 (37) | 32 (33) | 38 (41) |
> 24 months | 52 (28) | 23 (24) | 29 (31) |
Unknown | 13 (7) | 9 (9) | 4 (4) |
Median platinum-free interval (months) | 16.5 (6-119) | 14.8 (6-96) | 17.3 (6-119) |
CA 125 at baseline | Â | Â | Â |
Median (range) | 207 (4-6000) | 210 (7-6000) | 199 (4-3400) |